NCI-2024-07040

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd), A B7-H3 ANTIBODY DRUG CONJUGATE (ADC), VERSUS TREATMENT OF PHYSICIANS CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDeate-Lung02)

The IDeate-Lung02 study is a Phase 3, multicenter, randomized, open-label research study evaluating a novel drug called Ifinatamab Deruxtecan (I-DXd) in people with relapsed small cell lung cancer (SCLC). Ifinatamab Deruxtecan is an antibody–drug conjugate (ADC) designed to target a protein called B7-H3, which is found in high levels on many cancer cells, including small cell lung cancer, but in low amounts on normal cells. The drug works by binding to B7-H3 on tumor cells, delivering a potent chemotherapy payload directly into them to destroy the cancer while limiting harm to healthy tissues. The goal of the IDeate-Lung02 trial is to see whether Ifinatamab Deruxtecan can offer a more effective and targeted treatment option for people with relapsed or treatment-resistant small cell lung cancer, a condition that currently has very limited therapeutic choices.

Phase 3: A phase 3 clinical trial is a large-scale study designed to assess the effectiveness and safety of a new medical treatment or approach compared to a standard treatment

Randomized: Patients are randomly assigned to one of two groups. It's like flipping a coin to decide who gets which treatment

Open Label: Patients know which treatments are being given to them

Small cell lung cancer: A type of lung cancer with small cells that grow too much and can spread to other parts of the body

Antibody-drug conjugate: an antibody that targets cancer cells and a chemotherapy drug that kills cancer cells.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06203210

Clinical Trial Site: Einstein

To see all available clinical trials click here.